Why the study?
Does the addition of stress/rest gated perfusion SPECT variables to clinical risk factors improve prognostic risk stratification for major cardiac events in patients with known coronary artery disease?
Does the addition of stress/rest gated perfusion SPECT variables to clinical risk factors improve prognostic risk stratification for major cardiac events in patients with known coronary artery disease?
Stress/rest gated perfusion SPECT provides significant incremental prognostic value over standard clinical risk factors for predicting major cardiac events in patients with established coronary artery disease.
Supports gated SPECT for prognostication in known CAD; leaves open impact on management or outcomes.
BACKGROUND: This study aimed to reveal the incremental prognostic implications of perfusion/function variables by stress/rest gated single-photon emission computed tomography (SPECT) over clinical risks in patients with known coronary artery disease (CAD). METHODS AND RESULTS: Using the Japanese Assessment of Cardiac Events and Survival Study by Quantitative Gated SPECT (J-ACCESS) database, the 3-year follow-up data of 2,200 patients who had established CAD were analyzed. Major cardiac events (cardiac death, myocardial infarction, heart failure, and unstable angina) were observed in 167 (7.6%) patients. Multivariate logistic regression analysis identified peripheral artery disease, diabetes mellitus, no use of statins, typical chest pain, pharmacological stress test, heart rate at rest, left ventricular end-systolic volume index derived from gated SPECT (LVESVI), and summed difference score (SDS) as independent significant predictors of the major cardiac events, with odds ratios of 1.025 to 2.291 (P=0.0309-0.0008). Global chi-square values increased by combining the independent predictors, and the greatest values (nearly 110) were observed when LVESVI or SDS was added to the pre-scan clinical information. CONCLUSIONS: Perfusion/function measures by stress/rest gated SPECT contribute to a significant improvement in risk stratification and secondary prevention strategy in combination with pre-scan clinical risks in patients with known CAD.
No takes yet. Share an insight, caveat, or question.
Hashimoto et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: